Mendez R, Iwaki Y, Mendez R, Bogaard T, Volpicelli M
J Urol. 1982 Mar;127(3):427-9. doi: 10.1016/s0022-5347(17)53846-x.
The effectiveness of deliberate pre-transplant blood transfusions was compared in randomly transfused and nontransfused patients who acted as controls at a single transplant center. The patients in the pre-transplant transfusion group who had never been transfused had better graft survival than all other groups. Next, were those patients who had previous random transfusions and were then placed in the deliberately transfused group. Those who had received random blood transfusions but were not in the protocol and those patients who never had transfusions did the poorest. Those patients never transfused previously who received the scheduled transfusions had far lower levels of antibodies than those who had had previous transfusions and those with previous transfusions who were then entered into the prospective transfusion protocol. The patients who had B cold cytotoxic antibodies had the highest graft survival rates. Timing was important, with the group receiving the last transfusions 3 to 6 weeks before transplantation doing significantly better than any other group. Histocompatibility locus-A and B antigen distribution among the groups did not bias the data.
在一个单一的移植中心,对随机输血患者和作为对照的未输血患者进行比较,以研究预先进行的移植前输血的效果。移植前输血组中从未接受过输血的患者,其移植物存活率高于所有其他组。其次是那些先前接受过随机输血,随后被纳入有意输血组的患者。那些接受过随机输血但未纳入方案的患者以及从未接受过输血的患者情况最差。先前从未输血但接受了预定输血的患者,其抗体水平远低于那些先前接受过输血的患者以及先前接受过输血且随后进入前瞻性输血方案的患者。具有B型冷细胞毒性抗体的患者移植物存活率最高。时间很重要,在移植前3至6周接受最后一次输血的组比其他任何组的情况都要好得多。各组织相容性位点A和B抗原分布在各群体之间并没有使数据产生偏差。